CHMP Gives Thumbs Up for Celltrion, Formycon Biosimilars

June 25, 2022

The European Committee for Medicinal Products for Human Use (CHMP) recommended 2 biosimilars for approval: Celltrion Healthcare’s bevacizumab candidate and Formycon’s prospective ranibizumab product.

The Top 5 Biosimilar Articles for the Week of June 20
Formycon: Biosimilar Acquisitions, Developments Signal Hope Despite Losses
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
EHA Abstracts Preview Potential for Eculizumab Contenders